Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Review, H1 2016', provides in depth analysis on Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted pipeline therapeutics. The report provides comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics and enlists all their major and minor projects - The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) Overview 6 Therapeutics Development 7 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Stage of Development 7 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Therapy Area 8 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Indication 9 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Pipeline Products Glance 10 Early Stage Products 10 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Companies 11 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Products under Development by Universities/Institutes 13 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Companies Involved in Therapeutics Development 20 Agilvax, Inc. 20 Bavarian Nordic A/S 21 Emergent BioSolutions Inc. 22 F. Hoffmann-La Roche Ltd. 23 Trellis Bioscience, Inc. 24 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Drug Profiles 25 Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 MVA-RSV - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 respiratory syncytial virus (virus like particle) vaccines - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 respiratory syncytial virus vaccine - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 respiratory syncytial virus vaccine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 respiratory syncytial virus vaccine - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 TRL-3D3 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Dormant Projects 33 Respiratory Syncytial Virus Attachment Glycoprotein (G or RSV-G) - Featured News & Press Releases 34 May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations 34 Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus 34 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Products under Investigation by Universities/Institutes, H1 2016 14 Assessment by Monotherapy/Combination Products, H1 2016 15 Number of Products by Stage and Mechanism of Action, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Agilvax, Inc., H1 2016 20 Pipeline by Bavarian Nordic A/S, H1 2016 21 Pipeline by Emergent BioSolutions Inc., H1 2016 22 Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 23 Pipeline by Trellis Bioscience, Inc., H1 2016 24 Dormant Projects, H1 2016 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.